|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
FACULTY AFFILIATIONS
 |
Julie R Gralow, MD Associate Professor, Medical Oncology University of Washington and Fred Hutchinson Cancer Research Center Seattle, Washington |
 |
John F R Robertson, MD Professor of Surgery Head of Academic Division of Breast Surgery University of Nottingham City Hospital Nottingham, United Kingdom |
 |
Clifford Hudis, MD Chief, Breast Cancer Medicine Service Solid Tumor Division Memorial Sloan-Kettering Cancer Center New York, New York |
 |
George W Sledge Jr, MD Ballve-Lantero Professor of Oncology Professor of Medicine and Pathology Indiana University School of Medicine Indianapolis, Indiana |
 |
Edith A Perez, MD Professor of Medicine Mayo Medical School Director, Cancer Clinical Study Unit Director, Breast Cancer Program, Division of Hematology and Oncology, Mayo Clinic Jacksonville, Florida |
 |
Norman Wolmark, MD Professor and Chairman Department of Human Oncology Allegheny General Hospital Professor, Drexel University College of Medicine Chairman, National Surgical Adjuvant Breast and Bowel Project Pittsburgh, Pennsylvania |
Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Chris Thomson, MD, MS and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc; Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Genentech BioOncology/OSI Pharmaceuticals, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.
In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:
Dr Gralow — Consulting Fees: Amgen Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech Inc, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Genentech Inc, Roche Laboratories Inc. Dr Hudis — Consulting Fees: Amgen Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: AstraZeneca Pharmaceuticals LP, Genentech Inc; Ownership Interest: Genomic Health Inc. Dr Perez — Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech Inc, Eli Lilly and Company, Pfizer Inc, Sanofi-Aventis. Dr Robertson — Consulting Fees: AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporation, Pfizer Inc, Schering AG; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporation, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporation, Schering AG. Dr Sledge — Consulting Fees: Genentech Inc, Roche Laboratories Inc; Contracted Research: Sanofi-Aventis. Dr Wolmark — Consulting Fees: Sanofi-Aventis.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
 |
 |
Editor’s Note:
Let’s get this thing done.
Prologue:
The adjuvant trastuzumab clinical research to
practice model
- Select publications
Breast Cancer Clinical Trials:
Neoadjuvant Therapy
 |
 |
 |
 |
 |
